Genomic Expression

INVEST

RNA expression is the dynamic
signal of health and disease.
By analyzing RNA, we can detect disease, monitor health, and design next-generation cures
RNA is the software of biology, and today, RNA is programmable
We started in oncology
Saving patients lives today and bending the time and cost curve for drug discovery and development tomorrow
All mRNAs
Quantitative whole transcriptome, not a fixed, limited gene panel
Close to 100%
diagnostic yield matching all patients to approved drugs
CLIA · reimbursed
Clinically validated and RNA-seq-specific payor code
For Clinicians
Plan for when the treatment stops working or recurs - find the drug or trial with close to 100% diagnostic yield.
For Pharma
Validate targets and build companion diagnostics on real patient RNA and bend your time and cost curve.
For Hospitals
Run an RNA AI platform in your own CLIA lab: better outcomes today, new revenue and new targets tomorrow
For Investors
Back the RNA AI layer, the $100B+ diagnostic sequencing market is missing, validated, and reimbursed
Contact
We'll get in touch with you soon
Name

Email

By continuing, you agree to our Terms & Conditions and Privacy Policy.

Comment
WHO WE ARE
Experienced Management Team with Startup RNA

Gitte Pedersen
CEO and co-founder
Gitte Pedersen, CEO is a former executive at Novo Nordisk. She has advised the Danish Government and early-stage biotech companies regarding their corporate development in the US

Follow on LinkedIn
Morten Pedersen
CSO and cofounder
Morten Pedersen, CSO and co-founder, has a strong track record of innovation with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies

Jesper Zeuthen
CMO Oncology research
Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.
RECOGNIZED BY
Genomic Expression's team has brought the company from idea to commercialization through grants, revenue, and angel funding, and is now implementing capabilities to rapidly translate RNA code into novel RNA Therapeutics in collaboration with Biotech and Pharma. We have accomplished that with grants from the Danish Innovation Fund, Horizon Europe, EuroStars, US National Cancer Institute, and our investors from Pipeline Angels and Harvard Business Angels, among others. We got featured in Forbes and won numerous awards from the Extreme Technology Competition, Europe Top50, EIC Life Science Award and the semifinals of the XPRIZE competition
Awards

Top 10 XTC
MedTech Innovator Top 50
Winner of the EIC Lifescience Award
Featured in Forbes
In the semi-finals of the XPRIZE for Rapid Covid Testing
WANT TO LEARN MORE?

DISCLAIMER The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.